Physician profile
Rita Jain
NPI 1275513731
$11,427.68
in general payments reported to CMS, 2019-2025
47 companies · $2,047 in 2025
The $2,047 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,614 · 2020: $1,547 · 2021: $1,309 · 2022: $1,867 · 2023: $1,884 · 2024: $1,160 · 2025: $2,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,068 · Education: $22.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,068.14 |
| Education | $22.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $1,443.23 | 2019-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $1,274.49 | 2019-2025 | |
| Lilly USA, LLC | $815.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $751.40 | 2019-2025 | |
| Novo Nordisk INC | $732.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $678.35 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $672.22 | 2020-2025 | Tepezza, Evenity, Prolia |
| Astrazeneca Pharmaceuticals Lp | $587.57 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $516.14 | 2019-2023 | Segluromet, Steglatro, Steglujan |
| Abbott Laboratories | $465.88 | 2021-2025 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $353.81 | 2020-2025 | Unithroid |
| Mannkind Corporation | $339.29 | 2019-2023 | Afrezza |
| Xeris Pharmaceuticals, INC. | $320.92 | 2020-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $297.56 | 2023-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $259.47 | 2022-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $255.19 | 2019-2020 | |
| Insulet Corporation | $233.04 | 2020-2024 | Omnipod |
| Dexcom, INC. | $140.58 | 2021-2023 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $124.07 | 2025 | Yorvipath |
| Recordati_rare_diseases_inc. | $115.51 | 2023-2025 | Signifor Lar, Isturisa |
| Medtronic, INC. | $108.55 | 2021-2023 | Minimed 780g |
| Zealand Pharma US, INC. | $90.18 | 2021-2022 | |
| Halozyme INC | $77.62 | 2023 | |
| Pfizer INC. | $71.20 | 2023-2025 | |
| Shire North American Group INC | $68.65 | 2019 | |
| Antares Pharma, INC. | $59.28 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Lifescan, INC. | $55.54 | 2019-2023 | |
| Tolmar, INC. | $49.80 | 2023-2025 | Jatenzo |
| Tandem Diabetes Care, INC. | $49.54 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Valeritas, INC. | $49.29 | 2019 | |
| Clarus Therapeutics INC. | $36.84 | 2021 | |
| Ibsa Pharma INC. | $35.61 | 2021-2023 | Tirosint, Licart |
| Madrigal Pharmaceuticals | $35.29 | 2025 | Rezdiffra |
| Amarin Pharma, INC. | $34.64 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $23.79 | 2021 | |
| Ascensia Diabetes Care US INC. | $22.47 | 2024 | |
| Almatica Pharma LLC | $21.82 | 2024 | Loreev Xr, Teriparatide |
| Sequel Med Tech, LLC | $18.94 | 2025 | Twiist |
| Vistapharm, INC. | $18.92 | 2021 | |
| Glaxosmithkline, LLC. | $18.73 | 2025 | Arexvy, Shingrix |
| Medicure Pharma INC. | $18.38 | 2025 | Zypitamag |
| Amryt Pharma Holdings Ltd | $18.11 | 2022 | |
| Sandoz INC. | $15.11 | 2025 | Jubbonti |
| Acella Pharmaceuticals, LLC | $14.77 | 2025 | NP Thyroid 60 |
| Grt US Holding, INC. | $13.45 | 2021 | |
| Becton, Dickinson and Company | $13.28 | 2019 | |
| Acerus Pharmaceuticals Corporation | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.